Format

Send to

Choose Destination
J Thromb Haemost. 2015 Jun;13 Suppl 1:S281-9. doi: 10.1111/jth.12924.

Use of genetic data to guide therapy in arterial disease.

Ross S1,2,3, Nejat S1,4, Paré G1,2,3,4,5.

Author information

1
Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.
2
Department of Clinical Epidemiology & Biostatistics, Population Genomics Program, McMaster University, Hamilton, ON, Canada.
3
Population Genomics Program, Chanchlani Research Centre, McMaster University, Hamilton, ON, Canada.
4
Department of Pathology & Molecular Medicine, McMaster University, Hamilton, ON, Canada.
5
Thrombosis & Atherosclerosis Research Institute, Hamilton Health Sciences & McMaster University, Hamilton, ON, Canada.

Abstract

There is considerable interindividual variation in the response to antiplatelet and anticoagulant therapies. It has been proposed that this variability in drug response may be attributable to genetic variants. Thus, pharmacogenetics may help to accurately predict response to cardiovascular disease (CVD) therapies in order to maximize drug efficacy, minimize drug toxicity, and to tailor personalized care for these patients. Although the clinical utility of pharmacogenetics is promising, its adoption in clinical practice has been slow. This resistance may stem from sometimes conflicting findings among pharmacogenetic studies. Thus, this review focuses on the genetic determinants of commonly used platelet antagonists and anticoagulants including aspirin, clopidogrel, dabigatran, and warfarin. We also explore the clinical translation of pharmacogenetics in the management of patients with CVD.

KEYWORDS:

anticoagulants; cardiovascular diseases; genetics; pharmacogenetics; platelet aggregation inhibitors

PMID:
26149037
DOI:
10.1111/jth.12924
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center